ANDA 76770, held by Chartwell Injectable. Terbutaline Sulfate.
As of Nov 16, 2026, ANDA 76770 (Terbutaline Sulfate), held by Chartwell Injectable, was first approved by FDA on Apr 23, 2004, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 23, 2004 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Terbutaline Sulfate1MG/ML ยท injectable;injection | Terbutaline Sulfate | Discontinued |
| Apr 8, 2011 | Supplement 6Labeling | Approved | None posted |
| Apr 23, 2004 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters